These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 18767939)

  • 1. Telomerase as a universal tumor antigen for cancer vaccines.
    Beatty GL; Vonderheide RH
    Expert Rev Vaccines; 2008 Sep; 7(7):881-7. PubMed ID: 18767939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Universal tumor antigens for cancer vaccination: targeting telomerase for immunoprevention.
    Vonderheide RH
    Discov Med; 2007 Aug; 7(39):103-8. PubMed ID: 18093471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase.
    Vonderheide RH; Anderson KS; Hahn WC; Butler MO; Schultze JL; Nadler LM
    Clin Cancer Res; 2001 Nov; 7(11):3343-8. PubMed ID: 11705846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomerase as a universal tumor-associated antigen for cancer immunotherapy.
    Vonderheide RH
    Oncogene; 2002 Jan; 21(4):674-9. PubMed ID: 11850795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immunogenicity of the hTERT540-548 peptide in cancer.
    Wenandy L; Sørensen RB; Sengeløv L; Svane IM; thor Straten P; Andersen MH
    Clin Cancer Res; 2008 Jan; 14(1):4-7. PubMed ID: 18172245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer immunotherapy targeting the telomerase reverse transcriptase.
    Huo LF; Tang JW; Huang JJ; Huang PT; Huang CF; Kung HF; Lin MC
    Cell Mol Immunol; 2006 Feb; 3(1):1-11. PubMed ID: 16549043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uses of telomerase peptides in anti-tumor immune therapy.
    Li H; Katik I; Liu JP
    Methods Mol Biol; 2007; 405():61-86. PubMed ID: 18369818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Human telomerase reverse transcriptase as a novel target for tumor immunotherapy].
    Pang JX
    Ai Zheng; 2003 Aug; 22(8):893-5. PubMed ID: 12917043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells.
    Kokhaei P; Palma M; Hansson L; Osterborg A; Mellstedt H; Choudhury A
    Exp Hematol; 2007 Feb; 35(2):297-304. PubMed ID: 17258078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of a recombinant lentiviral vector carrying human telomerase tumor antigen in HLA-B*0702 transgenic mice.
    Rusakiewicz S; Dosset M; Mollier K; Souque P; Charneau P; Wain-Hobson S; Langlade-Demoyen P; Adotévi O
    Vaccine; 2010 Aug; 28(38):6374-81. PubMed ID: 20654669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunity against breast cancer by TERT DNA vaccine primed with chemokine CCL21.
    Yamano T; Kaneda Y; Hiramatsu SH; Huang S; Tran AN; Giuliano AE; Hoon DS
    Cancer Gene Ther; 2007 May; 14(5):451-9. PubMed ID: 17318199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The preparation of myeloma-specific T cells activated with dendritic cells loaded with nonapeptides derived from mucin protein MUC1 and catalytic subunit of telomerase hTERT].
    Ocadlíková D; Kovárová L; Hájek R; Michálek J
    Klin Onkol; 2008; 21(2):59-65. PubMed ID: 19102213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals.
    Vonderheide RH; Schultze JL; Anderson KS; Maecker B; Butler MO; Xia Z; Kuroda MJ; von Bergwelt-Baildon MS; Bedor MM; Hoar KM; Schnipper DR; Brooks MW; Letvin NL; Stephans KF; Wucherpfennig KW; Hahn WC; Nadler LM
    Cancer Res; 2001 Dec; 61(23):8366-70. PubMed ID: 11731409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients.
    Danet-Desnoyers GA; Luongo JL; Bonnet DA; Domchek SM; Vonderheide RH
    Exp Hematol; 2005 Nov; 33(11):1275-80. PubMed ID: 16263411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospects and challenges of building a cancer vaccine targeting telomerase.
    Vonderheide RH
    Biochimie; 2008 Jan; 90(1):173-80. PubMed ID: 17716803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melanoma cancer vaccines and anti-tumor T cell responses.
    Vujanovic L; Butterfield LH
    J Cell Biochem; 2007 Oct; 102(2):301-10. PubMed ID: 17647270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From genomics to cancer vaccines: patient-tailored or universal vaccines?
    Nadler LM; Schultze JL
    Curr Opin Mol Ther; 2002 Dec; 4(6):572-6. PubMed ID: 12596359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel peptide-nucleotide dual vaccine of human telomerase reverse transcriptase induces a potent cytotoxic T-cell response in vivo.
    Guo H; Hao J; Wu C; Shi Y; Zhao XY; Fang DC
    Biochem Biophys Res Commun; 2007 Jun; 357(4):1090-5. PubMed ID: 17462602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telomerase in cancer immunotherapy.
    Liu JP; Chen W; Schwarer AP; Li H
    Biochim Biophys Acta; 2010 Jan; 1805(1):35-42. PubMed ID: 19751801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer.
    Mennuni C; Ugel S; Mori F; Cipriani B; Iezzi M; Pannellini T; Lazzaro D; Ciliberto G; La Monica N; Zanovello P; Bronte V; Scarselli E
    Cancer Res; 2008 Dec; 68(23):9865-74. PubMed ID: 19047167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.